Yilei Mao

Prof. Dr. Yilei Mao

Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
WLWenjun Liao
Wenjun Liao
HYHuayu Yang
Huayu Yang
HXHaifeng Xu
Haifeng Xu
YWYanan Wang
Yanan Wang
PGPenglei Ge
Penglei Ge
YMYilei Mao
Yilei Mao
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing Noninvasive Detection of Tumor-Associated Mutations from Circulating cell-free DNA in Hepatocellular Carcinoma Patients by Targeted Deep Sequencing

1 October 2019 in Annals of Translational Medicine
Verified
Journal Article
Closed access
PDF file
MLMeixi Liu
Meixi Liu
HYHuayu Yang
Huayu Yang
YMYilei Mao
Yilei Mao
Magnesium is a vital cation that takes part in many cellular processes. Magnesium balance can be disturbed in multiple conditions, and differences in magnesium concentration can be responsible for numerous physiological and pathological processes. Magnesium deficiency is commonly associated with liver diseases, and may result from low nutrient uptake, greater urinary secretion, low serum albumin concentration, or hormone inactivation. In turn, low magnesium content in serum and liver tissue can lead to the progression of these diseases, due to a disruption in mitochondrial function, defective protein kinase C (PKC) translocation, inflammatory responses, oxidative stress, or metabolic disorders. Furthermore, magnesium supplementation can improve liver function in certain liver diseases. This paper comprehensively reviews the changes in magnesium concentrations associated with liver cirrhosis, alcoholic liver disease (ALD), liver cancer, and viral hepatitis, and explains how such changes may in turn impact these disease processes.

1 August 2014 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
PGPeng-Lei Ge
Peng-Lei Ge
SDShun-Da Du
Shun-Da Du
YMYilei Mao
Yilei Mao

1 January 2016 in Cancer Biology & Medicine
Verified
Journal Article
Open access
YRYao Rui
Yao Rui
XGXu Gang
Xu Gang
MSMao Shuang-Shuang
Mao Shuang-Shuang
YHYang Hua-Yu
Yang Hua-Yu
SXSang Xin-Ting
Sang Xin-Ting
YMYilei Mao
Yilei Mao
Three-dimensional (3D) printing (3DP) is a rapid prototyping technology that has gained increasing recognition in many different fields. Inherent accuracy and low-cost property enable applicability of 3DP in many areas, such as manufacturing, aerospace, medical, and industrial design. Recently, 3DP has gained considerable attention in the medical field. The image data can be quickly turned into physical objects by using 3DP technology. These objects are being used across a variety of surgical specialties. The shortage of cadaver specimens is a major problem in medical education. However, this concern has been solved with the emergence of 3DP model. Custom-made items can be produced by using 3DP technology. This innovation allows 3DP use in preoperative planning and surgical training. Learning is difficult among medical students because of the complex anatomical structures of the liver. Thus, 3D visualization is a useful tool in anatomy teaching and hepatic surgical training. However, conventional models do not capture haptic qualities. 3DP can produce highly accurate and complex physical models. Many types of human or animal differentiated cells can be printed successfully with the development of 3D bio-printing technology. This progress represents a valuable breakthrough that exhibits many potential uses, such as research on drug metabolism or liver disease mechanism. This technology can also be used to solve shortage of organs for transplant in the future.

1 April 2015 in Medicine
Verified
Journal Article
Open access
WLWenjun Liao
Wenjun Liao
YMYilei Mao
Yilei Mao
PGPenglei Ge
Penglei Ge
HYHuayu Yang
Huayu Yang
HXHaifeng Xu
Haifeng Xu
SZShouxian Zhong
Shouxian Zhong
Qualitative and quantitative analyses of circulating cell-free DNA (cfDNA) are potential methods for the detection of hepatocellular carcinoma (HCC). Many studies have evaluated these approaches, but the results have been variable. This meta-analysis is the first to synthesize these published results and evaluate the use of circulating cfDNA values for HCC diagnosis. All articles that met our inclusion criteria were assessed using QUADAS guidelines after the literature research. We also investigated 3 subgroups in this meta-analysis: qualitative analysis of abnormal concentrations of circulating cfDNA; qualitative analysis of single-gene methylation alterations; and multiple analyses combined with alpha-fetoprotein (AFP). Statistical analyses were performed using the software Stata 12.0. We synthesized these published results and calculated accuracy measures (pooled sensitivity and specificity, positive/negative likelihood ratios [PLRs/NLRs], diagnostic odds ratios [DORs], and corresponding 95% confidence intervals [95% CIs]). Data were pooled using bivariate generalized linear mixed model. Furthermore, summary receiver operating characteristic curves and area under the curve (AUC) were used to summarize overall test performance. Heterogeneity and publication bias were also examined. A total of 2424 subjects included 1280 HCC patients in 22 studies were recruited in this meta-analysis. Pooled sensitivity and specificity, PLR, NLR, DOR, AUC, and CIs of quantitative analysis were 0.741 (95% CI: 0.610-0.840), 0.851 (95% CI: 0.718-0.927), 4.970 (95% CI: 2.694-9.169), 0.304 (95% CI: 0.205-0.451), 16.347 (95% CI: 8.250-32.388), and 0.86 (95% CI: 0.83-0.89), respectively. For qualitative analysis, the values were 0.538 (95% CI: 0.401-0.669), 0.944 (95% CI: 0.889-0.972), 9.545 (95% CI: 5.298-17.196), 0.490 (95% CI: 0.372-0.646), 19.491 (95% CI: 10.458-36.329), and 0.87 (95% CI: 0.84-0.90), respectively. After combining with AFP assay, the values were 0.818 (95% CI: 0.676-0.906), 0.960 (95% CI: 0.873-0.988), 20.195 (95% CI: 5.973-68.282), 0.190 (95% CI: 0.100-0.359), 106.270 (95% CI: 22.317-506.055), and 0.96 (95% CI: 0.94-0.97), respectively. The results in this meta-analysis suggest that circulating cfDNA have potential value for HCC diagnosis. However, it would not be recommended for using independently, which is based on the nonrobust results. After combining with AFP, the diagnostic performance will be improved. Further investigation with more data is needed.

1 August 2021 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
XYXiaobo Yang
Xiaobo Yang
HXHaifeng Xu
Haifeng Xu
BZBangyou Zuo
Bangyou Zuo
XYXu Yang
Xu Yang
JBJin Bian
Jin Bian
HZHaitao Zhao
Haitao Zhao
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy Xiaobo Yang, Haifeng Xu, Bangyou Zuo, Xu Yang, Jin Bian, Junyu Long, Dongxu Wang, Junwei Zhang, Cong Ning, Yanyu Wang, Ziyu Xun, Yunchao Wang, Xin Lu, Yilei Mao, Xinting Sang, Haitao Zhao